131 related articles for article (PubMed ID: 30941993)
1. Role of everolimus in the treatment of advanced neuroendocrine tumor: a meta-analysis of randomized trials.
Zhuo ZG; Zhu YK; Deng HY; Li G; Luo J; Alai GH; Lin YD
J BUON; 2019; 24(1):368-373. PubMed ID: 30941993
[TBL] [Abstract][Full Text] [Related]
2. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
[TBL] [Abstract][Full Text] [Related]
4. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
Rose DB; Nellesen D; Neary MP; Cai B
J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
6. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis.
Kaderli RM; Spanjol M; Kollár A; Bütikofer L; Gloy V; Dumont RA; Seiler CA; Christ ER; Radojewski P; Briel M; Walter MA
JAMA Oncol; 2019 Apr; 5(4):480-489. PubMed ID: 30763436
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.
Fazio N; Buzzoni R; Delle Fave G; Tesselaar ME; Wolin E; Van Cutsem E; Tomassetti P; Strosberg J; Voi M; Bubuteishvili-Pacaud L; Ridolfi A; Herbst F; Tomasek J; Singh S; Pavel M; Kulke MH; Valle JW; Yao JC
Cancer Sci; 2018 Jan; 109(1):174-181. PubMed ID: 29055056
[TBL] [Abstract][Full Text] [Related]
10. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).
Vernieri C; Pusceddu S; Fucà G; Indelicato P; Centonze G; Castagnoli L; Ferrari E; Ajazi A; Pupa S; Casola S; Foiani M; Mazzaferro V; Pruneri G; Milione M; de Braud F
Int J Cancer; 2019 Apr; 144(7):1704-1712. PubMed ID: 30520016
[TBL] [Abstract][Full Text] [Related]
11. Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors.
Ter-Minassian M; Zhang S; Brooks NV; Brais LK; Chan JA; Christiani DC; Lin X; Gabriel S; Dinet J; Kulke MH
Oncologist; 2017 Feb; 22(2):165-172. PubMed ID: 28179574
[TBL] [Abstract][Full Text] [Related]
12. How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies.
Pusceddu S; De Braud F; Lo Russo G; Concas L; Femia D; Vernieri C; Indini A; Formisano B; Buzzoni R
Oncotarget; 2016 Jul; 7(28):44841-44847. PubMed ID: 27057638
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors.
Lee A; Chan DL; Wong MH; Li BT; Lumba S; Clarke SJ; Samra J; Pavlakis N
Neuroendocrinology; 2017; 104(3):209-222. PubMed ID: 27082107
[TBL] [Abstract][Full Text] [Related]
14. Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):11-3. PubMed ID: 27168106
[No Abstract] [Full Text] [Related]
15. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
[TBL] [Abstract][Full Text] [Related]
16. Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis.
Roviello G; Zanotti L; Venturini S; Bottini A; Generali D
Cancer Biol Ther; 2016 Sep; 17(9):883-8. PubMed ID: 27414404
[TBL] [Abstract][Full Text] [Related]
17. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
Flaum N; Valle JW; Mansoor W; McNamara MG
Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069
[TBL] [Abstract][Full Text] [Related]
18. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials.
Fazio N; Carnaghi C; Buzzoni R; Valle JW; Herbst F; Ridolfi A; Strosberg J; Kulke MH; Pavel ME; Yao JC
Cancer; 2021 Aug; 127(15):2674-2682. PubMed ID: 33857327
[TBL] [Abstract][Full Text] [Related]
19. Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.
Capdevila J; Hernando J; Perez-Hoyos S; Roman-Gonzalez A; Grande E
Oncologist; 2019 Dec; 24(12):e1315-e1320. PubMed ID: 31332100
[TBL] [Abstract][Full Text] [Related]
20. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.
Lee L; Ito T; Jensen RT
Expert Opin Pharmacother; 2018 Jun; 19(8):909-928. PubMed ID: 29757017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
